Table 5 Clinical analysis of PGP expression in relation to response and relapse.
Reference | Sample | PGP+ patients | Antibodies | Sampling method | PGP threshold | Statistical test | Outcome | |
|---|---|---|---|---|---|---|---|---|
Relapse | No relapse | |||||||
[83] | PRE | 75% (15/20) | 12% (2/17) | JSB1, MRK16 | 2 samples per tumour, central and periphery | PGP- = ≤10%, PGP+ = >10% | Log rank | P < 0.001 |
[77] | PRE | 80% (12/15) | 13% (2/15) | C219, JSB1 | – | PGP- = ≤10%, PGP+ = >10% | Two-tailed Fischer’s exact | P = 0.001 |
[36] | PRE | 74% (17/23) | 40% (15/38) | C494, JSB1, MRK16 | – | – | Two-tailed Fischer’s exact | P = 0.01 |
[79] | PRE | 55% (30/55) | 18% (17/94) | C494, JSB1, MRK16 | – | PGP+ = diffused immunostaining | Two-tailed Fischer’s exact | P < 0.0001 |
[80] | PRE | 79% (27/34) | 43% (26/60) | C494, JSB1, MRK16 | – | PGP- = ≤10%, PGP+ = >10%, using 2/3 antibodies | Two-tailed Fischer’s exact | P = 0.001 |
Poor responder | Good responder | |||||||
[75] | PRE | 24% (6/25) | 33% (22/67) | C219, JSB1, MRK16 | – | PGP- = ≤10%, PGP+ = >10% | Log rank | P = 0.46 |
[28] | PRE | 48% (12/25) | 20% (4/20) | JSB1 | – | PGP- = ≤25%, PGP+ = >25% | Fischer’s exact | P = 0.066 |
[28] | POST | 88% (22/25) | 0% (0/20) | JSB1 | – | PGP- = ≤25%, PGP+ = >25% | Fischer’s exact | P < 0.001 |
[77] | PRE | 55% (6/11) | 75% (3/4) | C219, JSB1 | – | PGP- = ≤10%, PGP+ = >10% | Two-tailed Fischer’s exact | P = 0.604 |
[78] | PRE | 32% (8/25) | 45% (5/11) | C219, JSB1, MRK16 | 300 tumour cells | PGP- = ≤15%, PGP+ = >15% | – | NP |
[79] | PRE | 29% (13/45) | 33% (34/104) | C494, JSB1, MRK16 | – | PGP+ = diffused immunostaining | Two-tailed Fischer’s exact | P = 0.62 |
[80] | PRE | 55% (44/80) | 64% (9/14) | C494, JSB1, MRK16 | – | PGP- = ≤10%, PGP+ = >10% | Two-tailed Fischer’s exact | NP |
